BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, January 6, 2026
Home » Blogs » BioWorld MedTech Perspectives » Wearable med tech arrives at a plateau in Asian market as barriers to use increase

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Wearable med tech arrives at a plateau in Asian market as barriers to use increase

Nov. 17, 2016
By Haky Moon

SINGAPORE – The wearable med-tech space saw a heated flurry of activity over the last year across Asia, but enthusiasm has cooled considerably as the obstacles that lie ahead for the sector become more apparent.

Panelists speaking during the Asia Pacific Medtech Forum 2016 in Singapore emphasized that wearables will have to influence consumer behavior if they are to stay relevant.

"If you look at wearables now, they are not medical-grade devices. It's very difficult for hospitals and practitioners to use them. From a start up point of view, we need to step up to meet that need as a hospital," said Michel Birnbaum, entrepreneur-in-residence at NTUitive Pte Ltd., an innovation and enterprise company owned by Nanyang Technological University. "We need to raise our game as well, to get to the point where people consider us medical-graded."

"Fitbit measures heartbeats of human beings and it measures heartbeats in wooden desks as well," added Birnbuam.

Medical-device wearables tend to target one of the four most prevalent chronic illnesses: congestive heart failure, diabetes, hypertension and chronic obstructive pulmonary disease.

On average, three months after wearing a wearable, most users typically stop wearing them.

"What do you do with the results? That's the bigger question and if health tech addresses that, that will make them exponentially gain more traction," said Zubin Daruwalla, director at Pricewaterhousecoopers.

Case in point is San Francisco.-based Fitbit Inc., which announced its third-quarter earnings on Nov 3.

This year, the company's revenue was up 23 percent, but its stock plummeted more than 30 percent in 10 minutes due to a dismal outlook for the fourth quarter.

Fitbit, founded by James Park and Eric Friedman, is known for its products of the same name, which are activity trackers, wireless-enabled wearable technology devices that measure data such as the number of steps walked, heart rate, quality of sleep, steps climbed and other personal metrics.

In the U.S., Fitbit devices are used in diabetes and weight management programs by two of the largest U.S. health insurers. Its corporate wellness program, where companies give employees Fitbit activity trackers to encourage healthier lifestyles, generates less than 10 percent of revenue at present, but is growing in volume.

In spite of working with the largest U.S. health insurers, sales of Fitbit has grown a meager two to five percent this year, compared to last year's 94 percent growth.

Currently, wearable devices are mostly being developed for two main market segments. These are largely for medical and fitness purposes. The former is specific to patients and the latter enjoys a wider user base.

89 percent of wearable products are wrist-worn, in a form of smartwatches, and used mainly for monitoring heart rate, sleep quality and activity ambient temperature. The rest are most commonly worn on the ears, eyes and clothing.

With the push to make these wearables 'medical-grade', companies like Fitbit will face regulatory hurdles, having to gain approvals by the U.S. Food and Drug Administration through rigorous clinical trials.

"Another barrier would be regulations but that will depend on the market," said Birnbaum.

Despite dampened outlooks, a report by Pricewaterhousecoopers, 'The Digital healthcare Leap', published in August, predicts there will be an increasing influx of wearable solutions in emerging markets that will support demand for monitoring and tracking to be integrated into daily life.

Daruwalla, also an advisor for health tech start ups, pointed out that although wearables have hit a plateau, it hasn't hindered innovation. He sees start ups emerging to address issues.

"From what I have observed, companies that I would say are gaining traction are ones that collate that data and then take that extra step, and do something with it," said Daruwalla.

The current level of technology in wearables will have to be addressed, but the medical wearables market in Asia is expected to grow due to several factors.

These are a combination of a rise in health care spending by the government and individuals and a huge jump in diabetes and heart disease incidence.

The World Health Organization estimated that the number of annual cardiovascular events in China will increase by more than 50 percent by 2030. The number of people with diabetes in India is now at 67 million.

Imedia Research and the International Data Corp. predict this will push wearable device sales upwards to 13 million units in Japan by 2017 and a whopping 4.7 billion units in China by 2020.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 6, 2026.
  • Sickle cell illustration

    AND-017 increases RBC and hemoglobin in sickle cell disease

    BioWorld Science
    Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
  • 3D rendering of antibody drug conjugated with cytotoxic payload

    ADCs’ breakout 2025 and their still-unfinished potential

    BioWorld Science
    Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
  • Icons representing scientific research

    Science in 2025: the best of the rest

    BioWorld Science
    A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing